Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

165 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
TERT promoter mutation confers favorable prognosis regardless of 1p/19q status in adult diffuse gliomas with IDH1/2 mutations.
Arita H, Matsushita Y, Machida R, Yamasaki K, Hata N, Ohno M, Yamaguchi S, Sasayama T, Tanaka S, Higuchi F, Iuchi T, Saito K, Kanamori M, Matsuda KI, Miyake Y, Tamura K, Tamai S, Nakamura T, Uda T, Okita Y, Fukai J, Sakamoto D, Hattori Y, Pareira ES, Hatae R, Ishi Y, Miyakita Y, Tanaka K, Takayanagi S, Otani R, Sakaida T, Kobayashi K, Saito R, Kurozumi K, Shofuda T, Nonaka M, Suzuki H, Shibuya M, Komori T, Sasaki H, Mizoguchi M, Kishima H, Nakada M, Sonoda Y, Tominaga T, Nagane M, Nishikawa R, Kanemura Y, Kuchiba A, Narita Y, Ichimura K. Arita H, et al. Among authors: machida r. Acta Neuropathol Commun. 2020 Nov 23;8(1):201. doi: 10.1186/s40478-020-01078-2. Acta Neuropathol Commun. 2020. PMID: 33228806 Free PMC article.
TERT promoter mutation status is necessary and sufficient to diagnose IDH-wildtype diffuse astrocytic glioma with molecular features of glioblastoma.
Fujimoto K, Arita H, Satomi K, Yamasaki K, Matsushita Y, Nakamura T, Miyakita Y, Umehara T, Kobayashi K, Tamura K, Tanaka S, Higuchi F, Okita Y, Kanemura Y, Fukai J, Sakamoto D, Uda T, Machida R, Kuchiba A, Maehara T, Nagane M, Nishikawa R, Suzuki H, Shibuya M, Komori T, Narita Y, Ichimura K. Fujimoto K, et al. Among authors: machida r. Acta Neuropathol. 2021 Aug;142(2):323-338. doi: 10.1007/s00401-021-02337-9. Epub 2021 Jun 20. Acta Neuropathol. 2021. PMID: 34148105
Impact of postoperative complications on survival outcomes in patients with gastric cancer: exploratory analysis of a randomized controlled JCOG1001 trial.
Tokunaga M, Kurokawa Y, Machida R, Sato Y, Takiguchi S, Doki Y, Yabusaki H, Watanabe M, Hato S, Nakamori M, Ito S, Yoshikawa T, Terashima M. Tokunaga M, et al. Among authors: machida r. Gastric Cancer. 2021 Jan;24(1):214-223. doi: 10.1007/s10120-020-01102-3. Epub 2020 Jun 29. Gastric Cancer. 2021. PMID: 32601909
Possibility of a risk-adapted treatment strategy for untreated aggressive adult T-cell leukaemia-lymphoma (ATL) based on the ATL prognostic index: a supplementary analysis of the JCOG9801.
Toyoda K, Tsukasaki K, Machida R, Kadota T, Fukushima T, Ishitsuka K, Maruyama D, Nagai H. Toyoda K, et al. Among authors: machida r. Br J Haematol. 2019 Aug;186(3):440-447. doi: 10.1111/bjh.15950. Epub 2019 May 16. Br J Haematol. 2019. PMID: 31099033 Free article. Clinical Trial.
Risk factors for surgical site infection and association of surgical site infection with survival of lower rectal cancer patients without clinical lateral pelvic lymph node metastasis (clinical Stage II/III): Analysis of data from JCOG0212.
Katsumata K, Enomoto M, Ishizaki T, Fujita S, Kanemitsu Y, Ito M, Shiomi A, Komori K, Ohue M, Ota M, Akazai Y, Shiozawa M, Yamaguchi T, Bando H, Sekimoto M, Kobatake T, Machida R, Akasu T, Moriya Y; Colorectal Cancer Study Group of Japan Clinical Oncology Group. Katsumata K, et al. Among authors: machida r. Clin Exp Metastasis. 2021 Oct;38(5):459-466. doi: 10.1007/s10585-021-10117-8. Epub 2021 Aug 18. Clin Exp Metastasis. 2021. PMID: 34406563 Free PMC article.
165 results